bioRxiv Science⌕ Search
Home/Archive/bioRxiv

bioRxiv · 10.1101/062802

Possible Protective effect of Unani formulation against Isoproterenol induced toxicity in SVEC cells

Abdul M Kareem
View original source ↗Export metadata ↓

Abstract

Study BackgroundMain objective of the present study is to screen the protective efficiency of Khamira Gaozaban Ambari Jadwar Ood Saleeb Wala (KGAJOSW) a Unani formulation by using an experimentally induced toxicity model. Study mainly focused on the protective efficacy of the Unani formulation \"KGAJOSW\" with special emphasis to Isoproterenol (ISO) induced toxicity. This formulation has been referred as a \"cardio tonic\", both in ancient (Uddin Mk, 1967) and recent literatures (Ahmad et al, 2010) of Unanipathy. The outcome of this study will deliver the protective and non-toxic nature of the KGAJOSW. This will enhance the medicinal properties of other Unani formulation and making them non-toxic.\n\nExisting medicines and therapeutic procedures are target specific and have several post therapeutic complications like hypertension, Obesity, etc. Recent studies demonstrate that non-invasive treatment is the better way to treat and control development of chronic diseases like atherosclerosis. Due to these undesirable effects of synthetic drugs, the world population is turning towards medicines derived from locally available native extracts of edible plant parts and plants products, like Unani and Ayurveda.\n\nIn this context it is proposed to investigate the following objectives, which emphasis the lethality, ROS scavenging and expression of SOD-2 protein by KGAJOSW. The outcome of this study will focus on the mode of action and brief mechanisms operative at the \"cardio tonic\" level as affirmed for KGAJOSW in Unani pharmacopeia.\n\nObjectivesO_LITo identify the lethal dose of Isoproterenol and Unani formulation\nC_LIO_LITo measure Reactive Oxygen Species (ROS) levels\nC_LIO_LITo check the Superoxide dismutase2 (SOD2) protein and RNA expression\nC_LIO_LIWound healing assay to know the cell proliferation\nC_LI\n\nStudy designWe come-up with a pilot study to screen the protective as well as non-toxic effects of said Unani formulation. To achieve this we adopted a model of Isoproterenol (ISO) induced toxicity which is widely used to study the myocardial infarction in cells and animals. In this study we want to induce toxicity in simian virus derived murine endothelial cell line (SVEC) cells by treating with ISO and we were assuming this toxicity could be rescued by treating with Khamira (see the Schematic representation). We designed four experimental conditions like Untreated- SVEC cells without any treatment, ISO- SVEC cells receiving Isoproterenol, Khamira- SVEC cells receiving Unani formulation, ISO+Khamira- SVEC cells receiving both Isoproterenol and Khamira.\n\n\n\nO_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=133 SRC=\"FIGDIR/small/062802_ufig1.gif\" ALT=\"Figure 1\">\nView larger version (33K):\norg.highwire.dtl.DTLVardef@9b0ff7org.highwire.dtl.DTLVardef@354c86org.highwire.dtl.DTLVardef@132f9baorg.highwire.dtl.DTLVardef@1a93049_HPS_FORMAT_FIGEXP M_FIG C_FIG

Explore related subjects

Pharmacology and ToxicologyPreprint

Keep this discovery

BibTeXRIS

Abdul M Kareem. 2016-07-08. Possible Protective effect of Unani formulation against Isoproterenol induced toxicity in SVEC cells. https://doi.org/10.1101/062802

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

bioRxiv2016

Harnessing Big Data for Systems Pharmacology

Systems pharmacology aims to holistically understand genetic, molecular, cellular, organismal, and environmental mechanisms of drug actions through developing mechanistic or predictive models. Data-driven modeling plays a central role in systems pharmacology, and has already enabled biologists to generate novel hypotheses. However, more is needed. The drug response is associated with genetic/epigenetic variants and environmental factors, is coupled with molecular conformational dynamics, is affected by possible off-targets, is modulated by the complex interplay of biological networks, and is dependent on pharmacokinetics. Thus, in order to gain a comprehensive understanding of drug actions, systems pharmacology requires integration of models across data modalities, methodologies, organismal hierarchies, and species. This imposes a great challenge on model management, integration, and translation. Here, we discuss several upcoming issues in systems pharmacology and potential solutions to them using big data technology. It will allow systems pharmacology modeling to be findable, accessible, interoperable, reusable, reliable, interpretable, and actionable.

Pharmacology and Toxicology↗
bioRxiv2016

Insights into the binding mode of MEK type-III inhibitors. A step towards discovering and designing allosteric kinase inhibitors across the human kinome

Protein kinases are critical drug targets for treating a large variety of human diseases. Type-I and type-II kinase inhibitors frequently exhibit off-target toxicity or lead to mutation acquired resistance. Two highly specific allosteric type-III MEK-targeted drugs, Trametinib and Cobimetinib, offer a new approach. Thus, understanding the binding mechanism of existing type-III kinase inhibitors will provide insights for designing new type-III kinase inhibitors. In this work we have systematically studied the binding mode of MEK-targeted type-III inhibitors using structural systems pharmacology and molecular dynamics simulation. Our studies provide detailed sequence, structure, interaction-fingerprint, pharmacophore and binding-site information on the binding characteristics of MEK type-III kinase inhibitors. We propose that the helix-folding activation loop is a hallmark allosteric binding site for type-III inhibitors. Subsequently we screened and predicted allosteric binding sites across the human kinome, suggesting other kinases as potential targets suitable for type-III inhibitors. Our findings will provide new insights into the design of potent and selective kinases inhibitors.\n\nAuthor SummaryHuman protein kinases represent a large protein family relevant to many diseases, especially cancers, and have become important drug targets. However, developing the desired selective kinase-targeted inhibitors remain challenging. Kinase allosteric inhibitors provide that opportunity, but, to date, few have been designed other than MEK inhibitors. To more efficiently develop kinase allosteric inhibitors, we systematically studied the binding mode of the MEK type-III allosteric kinase inhibitors using structural system pharmacology and molecular dynamics approaches. New insights into the binding mode and mechanism of type-III inhibitors were revealed that may facilitate the design of new prospective type-III kinase inhibitors.

Pharmacology and Toxicology↗
bioRxiv2016

Clinically-weighted transcriptomic signatures for protein kinase inhibitor associated cardiotoxicity

Cardiotoxicity (CT) involving diminished cardiac contractility and heart failure is a major adverse event associated with otherwise efficacious protein kinase inhibitors (KIs). Here, we sought to develop clinically-weighted transcriptomic signatures to predict risk of CT and to better understand the biological processes associated with CT risk. We obtained transcriptome-wide response profiles in four human primary cardiomyocyte cell lines that were treated with 22 different KIs using mRNA sequencing with 3 digital gene expression. The FDA Adverse Event Reporting System was used to derive relative risk scores for four types of CT for different KIs. We used elastic net regression to associate these transcriptomic profiles with KI-associated risk scores for CT subtypes to obtain clinically-weighted transcriptomic signatures, which showed good predictive properties (cross-validation R2 >0.87). Our clinically-weighted transcriptomic signatures for KI-associated CT may be of relevance in early drug development for the prediction of KI-associated CT.

Pharmacology and Toxicology↗